HeraMEDASX:HMD +2.38% EBIT per Share is A$-0.00 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, HeraMED ranks better than 88.7% on this metric.
HeraMED's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 47.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for HeraMED's EBIT per Share or its related term are showing as below:
ASX:HMD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 11.8 Med: 25.6 Max: 47.7
Current: 47.7
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of HeraMED was 47.70% per year. The lowest was 11.80% per year. And the median was 25.60% per year.
ASX:HMD's 3-Year EBIT Growth Rate is ranked better than 88.7% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs ASX:HMD: 47.70
HeraMED's EBIT for the
six
months ended in Dec. 2025 was A$-1.88 Mil.
HeraMED (ASX:HMD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
HeraMED EBIT per Share Related Terms
HeraMED EBIT per Share Historical Data
* Premium members only.
The historical data trend for HeraMED's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeraMED (ASX:HMD) has a EBIT per Share of A$-0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HeraMED and its competitors. According to the industry distribution chart, HeraMED ranks #78 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 11.3%.
Is HeraMED's EBIT per Share too high?
HeraMED's current EBIT per Share is A$-0.00. Based on the distribution chart, HeraMED ranks #78 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does HeraMED's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HeraMED ranks #78 out of 690 companies for EBIT per Share. This places HeraMED in the top 11% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HeraMED and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeraMED's current EBIT per Share is A$-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 115% above its estimated fair value. The current EBIT per Share is A$-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current EBIT per Share is A$-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HMD has been successfully added to your 